

Olaparib

Printed from <https://www.cancerquest.org/node/6417> on 12/22/2024

Olaparib 2D



Brand name: Lynparza®

IUPAC: 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one

FDA approval: Yes

[Enlace del fabricante](#)

Usage:

Consider dose interruption or dose reduction to manage adverse reactions. Recommended dose reduction: 200 mg (four 50-mg capsules) PO BID. If a further final dose reduction is required, then reduce to 100 mg (two 50-mg capsules) PO BID.

Mechanism:

PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. In certain tumor cells, such as those from BRCA mutation carriers, blocking this enzyme can lead to cell death. Women who carry BRCA mutations are at a higher risk of developing some types of cancer, including ovarian and breast cancers.

Side effects:

Common side effects include nausea and vomiting , fatigue , diarrhea , indigestion , headache , appetite problems , common cold-like symptoms , cough , rash , pain in joints, muscles, bones, back, and abdomen.